Skip to main content

Cardiovascular Health

Lilly's Foundayo Cuts Cardiovascular Death Risk 53% in ACHIEVE-4 Trial

Lilly's Foundayo Cuts Cardiovascular Death Risk 53% in ACHIEVE-4 Trial

Indianapolis – – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its oral GLP-1 therapy Foundayo (orforglipron) reduced cardiovascular death risk by 53% and all-cause death risk by 57% compared with insulin glargine in the Phase 3 ACHIEVE-4 trial, the largest and longest study of the medicine in type 2 diabetes to date.

Foundayo meets non-inferiority bar on major cardiovascular events

Among 2,749 participants randomized across 16 countries including the U.S., Germany, India, Brazil and South Korea, Foundayo showed a 16% lower risk of MACE-4 (cardiovascular death, heart attack, stroke or hospitalization for unstable angina) versus insulin glargine, with a hazard ratio of 0.84 (95.0% CI: 0.59 to 1.20), meeting the prespecified non-inferiority threshold. The risk of MACE-3 (cardiovascular death, heart attack or stroke) was 23% lower (hazard ratio: 0.77; 95.0% CI: 0.52 to 1.13).

Ozempic Dose Escalation Cuts Cardiovascular Risk 6% Versus Mounjaro Switch

Ozempic Dose Escalation Cuts Cardiovascular Risk 6% Versus Mounjaro Switch

Plainsboro, N.J. – – September 29, 2026 -- Novo Nordisk reported that adults with type 2 diabetes who escalated their semaglutide dose to 2 mg showed a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared with patients who switched to tirzepatide, according to real-world data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan.

Retrospective analysis covers 636,525 patients on semaglutide 1 mg

The COMPETE SWITCH Cardiovascular study used Komodo Health's Healthcare Map claims database, spanning January 2018 to September 2025, to compare outcomes for patients escalating from semaglutide 1 mg to 2 mg against those switching to tirzepatide at doses up to 15 mg. The cardiovascular cohort included 185,705 adults who escalated to semaglutide 2 mg and 23,104 who switched to tirzepatide, tracked via an intention-to-treat approach for death, heart attack, and stroke.